0.31
+0.0193(+6.69%)
Currency In USD
| Previous Close | 0.29 |
| Open | 0.28 |
| Day High | 0.33 |
| Day Low | 0.25 |
| 52-Week High | 3.1 |
| 52-Week Low | 0.15 |
| Volume | 4.97M |
| Average Volume | 3.92M |
| Market Cap | 3.66M |
| PE | -0.1 |
| EPS | -3.06 |
| Moving Average 50 Days | 0.28 |
| Moving Average 200 Days | 0.82 |
| Change | 0.02 |
If you invested $1000 in Processa Pharmaceuticals, Inc. (PCSA) 10 years ago, it would be worth $1.69 as of June 04, 2025 at a share price of $0.308. Whereas If you bought $1000 worth of Processa Pharmaceuticals, Inc. (PCSA) shares 5 years ago, it would be worth $1.92 as of June 04, 2025 at a share price of $0.308.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 30, 2025 1:00 PM GMT
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced the
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
GlobeNewswire Inc.
Apr 15, 2025 12:00 PM GMT
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
GlobeNewswire Inc.
Mar 18, 2025 12:30 PM GMT
HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and